Share on StockTwits

Kindred Biosciences’ (NYSE:KIN) lock-up period is set to end on Tuesday, June 10th. Kindred Biosciences had issued 7,500,000 shares in its public offering on December 12th, Analyst Ratings News reports. The total size of the offering was $52,500,000 based on an initial share price of $7.00. After the end of Kindred Biosciences’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

A number of analysts have recently weighed in on KIN shares. Analysts at Craig Hallum initiated coverage on shares of Kindred Biosciences in a research note on Friday, May 23rd. They set a “buy” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Kindred Biosciences from $29.00 to $32.00 in a research note on Tuesday, May 13th. Finally, analysts at Roth Capital cut their price target on shares of Kindred Biosciences from $18.00 to $17.00 in a research note on Tuesday, May 13th. Three equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $26.33.

Shares of Kindred Biosciences (NYSE:KIN) traded up 6.74% during mid-day trading on Monday, hitting $17.644. The stock had a trading volume of 37,369 shares. Kindred Biosciences has a 52 week low of $8.75 and a 52 week high of $26.99. The stock has a 50-day moving average of $16.01 and a 200-day moving average of $17.2. The company’s market cap is $347.2 million.

Kindred Biosciences (NYSE:KIN) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.19. On average, analysts predict that Kindred Biosciences will post $-1.60 earnings per share for the current fiscal year.

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.